What is the BMS 927711?

BMS 927711 is , while it's Molecular Formula is C28H28F2N6O3.

What is the CAS number for BMS 927711?

The CAS number of BMS 927711 is 1289023-67-1.

What is BMS 927711 (1289023-67-1) used for?

Rimegepant (Nurtec ODT)(FDA approved in February 2020) is an ODT available in a single strength of 75 mg for the acute treatment of migraine with or without aura in adults.No more than 75 mg should be taken in a 24-hour period. while there are no contraindications，concomitant administration with CYP3A4 inhibitors should be avoided.The most common adverse reaction is nausea, occurring in few patients (rimegepant PI, 2020). In clinical trials, a single 75-mg dose of rimegepant demonstrated superiority over placebo with regard to freedom from pain (21% in the rimegepant group vs.11% in the placebo group) and freedom from the most bothersome symptom (35% vs. 27%) at 2 hours post dose (Croop et al., 2019). Rimegepant is not approved for migraine prevention, although it is presently in late-stage clinical trials assessing it for that indication(NCT03732638,2020).

What is the BMS 927711?

BMS 927711 is , while it's Molecular Formula is C28H28F2N6O3.

What is the CAS number for BMS 927711?

The CAS number of BMS 927711 is 1289023-67-1.

What is BMS 927711 (1289023-67-1) used for?

Rimegepant (Nurtec ODT)(FDA approved in February 2020) is an ODT available in a single strength of 75 mg for the acute treatment of migraine with or without aura in adults.No more than 75 mg should be taken in a 24-hour period. while there are no contraindications，concomitant administration with CYP3A4 inhibitors should be avoided.The most common adverse reaction is nausea, occurring in few patients (rimegepant PI, 2020). In clinical trials, a single 75-mg dose of rimegepant demonstrated superiority over placebo with regard to freedom from pain (21% in the rimegepant group vs.11% in the placebo group) and freedom from the most bothersome symptom (35% vs. 27%) at 2 hours post dose (Croop et al., 2019). Rimegepant is not approved for migraine prevention, although it is presently in late-stage clinical trials assessing it for that indication(NCT03732638,2020).

Product Class

1289023-67-1

Product Name：Rimegepant
Molecular Formula：C28H28F2N6O3
Purity：99%
Molecular Weight：534.566

Inquiry

Product Details:

CasNo： 1289023-67-1

Molecular Formula： C28H28F2N6O3

Buy High Quality Rimegepant,Best Quality 1289023-67-1 Reasonable Price

Molecular Formula:C28H28F2N6O3
Molecular Weight:534.566
PKA:12.03±0.20(Predicted)
PSA：119.39000
Density:1.45±0.1 g/cm3(Predicted)
LogP:5.54050

Rimegepant (Cas 1289023-67-1) Usage

Description

Rimegepant, marketed under the brand name Nurtec ODT, is a medication belonging to the class of calcitonin gene-related peptide (CGRP) receptor antagonists. It is specifically designed for the acute treatment of migraine headaches in adults, with or without aura. Additionally, it has been approved for the preventive treatment of episodic migraines in adults.

Clinical Uses

Rimegepant works by blocking the action of CGRP receptors, which are implicated in the pathogenesis of migraines. By targeting these receptors, rimegepant helps alleviate the symptoms associated with migraines, providing relief from pain and other bothersome symptoms commonly experienced during migraine attacks.

In terms of effectiveness, clinical trials have shown that a single dose of 75 mg rimegepant provides significant freedom from pain, pain relief, and freedom from the most bothersome symptom at two hours after administration. The orally disintegrating tablet formulation makes it convenient for administration, as it dissolves on or under the tongue.

Reactions

Common adverse reactions reported with rimegepant include nausea, dizziness, urinary tract infection, and liver injury. However, it is generally well-tolerated by most patients.

1289023-67-1 Relevant articles

Rimegepant oral disintegrating tablet for migraine

Lars Edvinsson

The Lancet, VOLUME 394, ISSUE 10200, P711-712, AUGUST 31, 2019

The trial was positive, showing an increase in relief from headache pain among the group receiving rimegepant at 2 h after dosing (10% over placebo) and improvement in the most bothersome symptoms, which included photophobia and nausea (8% over placebo).

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials

Bixi Gao&#x;Bixi Gao † Yanbo Yang&#x;Yanbo Yang † Zilan WangZilan Wang Yue SunYue Sun Zhouqing ChenZhouqing Chen Yun ZhuYun Zhu Zhong WangZhong Wang

, Front. Pharmacol., 24 January 2020

As one of the novel therapeutic drugs that targets Calcitonin gene-related peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine, which is one of the most common neurological diseases worldwide.

Discovery of (5S,6S,9R)-5-aqmino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro- 5H-cyclohepta[b]pyridin-9-yl4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate (BMS-927711): An oral Calcitonin Gene-Related Peptide (CGRP) antagonist in cinical trials for treating migraine

Luo, Guanglin,Chen, Ling,Conway, Charles M.,Denton, Rex,Keavy, Deborah,Signor, Laura,Kostich, Walter,Lentz, Kimberley A.,Santone, Kenneth S.,Schartman, Richard,Browning, Marc,Tong, Gary,Houston, John G.,Dubowchik, Gene M.,MacOr, John E.

, p. 10644 - 10651 (2013/02/23)

Calcitonin gene-related peptide (CGRP) r...

1289023-67-1 Upstream products

1190363-50-8
(5S,6S,9R)-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]-pyridin-5-ol
1289024-04-9
(5R,6S,9R)-5-chloro-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
1289024-05-0
(5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
1289024-06-1
(5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol

1289023-67-1 Downstream products

1289023-77-3
(5S,6S,9R)-6-(2,3-difluorophenyl)-5-(dimethylamino)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
1289023-74-0
(5S,6S,9R)-6-(2,3-difluorophenyl)-5-(methylamino)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate

Relevant Products

Pralsetinib
CAS：2097132-94-8
Etrasimod
CAS：1206123-37-6
Rivaroxaban intermediate
CAS：446292-08-6